Advertisement
Screener

ELI LILLY AND COMPANY (LLY) ROE

ELI LILLY & Co ROE

Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • ELI LILLY & Co roe for the quarter ending 2025-09-30 was 77.20%, a 32.09% increase year-over-year.
  • ELI LILLY & Co roe for the quarter ending 2025-06-30 was 75.21%, a 39.68% increase year-over-year.
  • ELI LILLY & Co roe for the quarter ending 2025-03-31 was 70.08%, a 47.26% increase year-over-year.
  • ELI LILLY & Co roe for the quarter ending 2024-12-31 was 74.20%, a 53.84% increase year-over-year.
  • ELI LILLY & Co roe for fiscal 2024 was 74.20%, a 53.84% increase from fiscal 2023.
  • ELI LILLY & Co roe for fiscal 2023 was 48.23%, a 16.77% decline from fiscal 2022.
  • ELI LILLY & Co roe for fiscal 2022 was 57.95%, a 4.95% decline from fiscal 2021.
  • ELI LILLY & Co roe for fiscal 2021 was 60.97%, a 42.66% decline from fiscal 2020.
Available history
2008-12-31 to 2025-09-30
Data captured

Historical ROE

DateROENet income 12 monthNet income 3 monthShareholder equity
2025-09-3077.20%$18.41B$5.58B$23.85B
2025-06-3075.21%$13.8B$5.66B$18.35B
2025-03-3170.08%$11.11B$2.76B$15.85B
2024-12-3174.20%$10.59B$4.41B$14.27B
2024-09-3058.44%$8.37B$970.30M$14.32B
2024-06-3053.84%$7.34B$2.97B$13.64B
2024-03-3147.59%$6.14B$2.24B$12.9B
2023-12-3148.23%$5.24B$2.19B$10.86B
2023-09-3044.12%$4.99B-$57.40M$11.31B
2023-06-3058.28%$6.5B$1.76B$11.15B
2023-03-3150.35%$5.69B$1.34B$11.29B
2022-12-3157.95%$6.24B$1.94B$10.78B
2022-09-3059.35%$6.03B$1.45B$10.17B
2022-06-3065.73%$5.69B$952.50M$8.66B
2022-03-3164.78%$6.13B$1.90B$9.46B
2021-12-3160.97%$5.58B$1.73B$9.15B
2021-09-3075.09%$5.97B$1.11B$7.95B
2021-06-3091.10%$6.07B$1.39B$6.66B
2021-03-3185.82%$6.09B$1.36B$7.1B
2020-12-31106.33%$6.19B$2.12B$5.83B
2020-09-30111.54%$5.57B$1.21B$5B
2020-06-30131.51%$5.62B$1.41B$4.27B
2020-03-31173.07%$5.53B$1.46B$3.2B
2019-12-31308.19%$8.32B$1.50B$2.7B
2019-09-30229.55%$7.95B$1.25B$3.46B
2019-06-30274.50%$7.84B$1.33B$2.86B
2019-03-31243.91%$6.26B$4.24B$2.57B
2018-12-3129.63%$3.23B$1.13B$10.91B
2018-09-303.18%$450.1M$1.15B$14.15B
2018-06-30-1.24%-$143.8M-$259.90M$11.62B
2018-03-317.71%$1.12B$1.22B$14.59B
2017-12-31-1.75%-$204.1M-$1.66B$11.67B
2017-09-3014.87%$2.22B$555.60M$14.96B
2017-06-3017.27%$2.45B$1.01B$14.17B
2017-03-3115.50%$2.19B-$110.80M$14.1B
2016-12-3119.44%$2.74B$771.80M$14.08B
2016-09-3015.65%$2.44B$778.00M$15.62B
2016-06-3016.82%$2.47B$747.70M$14.66B
2016-03-3115.43%$2.32B$440.10M$15.03B
2015-12-3116.51%$2.41B$478.40M$14.59B
2015-09-3015.47%$2.36B$799.70M$15.24B
2015-06-3014.00%$2.06B$600.80M$14.71B
2015-03-3114.67%$2.19B$529.50M$14.95B
2014-12-3115.53%$2.39B$428.50M$15.39B
2014-09-3015.21%$2.69B$500.60M$17.68B
2014-06-3018.85%$3.39B$733.50M$17.99B
2014-03-3121.06%$3.86B$727.90M$18.35B
2013-12-3126.56%$4.68B$727.50M$17.64B
2013-09-3028.32%$4.78B$1.20B$16.9B
2013-06-3032.21%$4.91B$1.21B$15.24B
2013-03-3130.93%$4.63B$1.55B$14.96B
2012-12-3127.67%$4.09B$827.20M$14.77B
2012-09-3025.66%$4.12B$1.33B$16.06B
2012-06-3028.16%$4.03B$923.60M$14.31B
2012-03-3129.03%$4.3B$1.01B$14.82B
2011-12-3132.12%$4.35B$858.20M$13.54B
2011-09-3030.94%$4.66B$1.24B$15.06B
2011-06-3033.10%$4.73B$1.20B$14.28B
2011-03-3135.00%$4.88B$1.06B$13.93B
2010-12-3140.84%$5.07B$1.17B$12.41B
2010-09-3038.82%$4.82B$1.30B$12.41B
2010-06-3043.52%$4.45B$1.35B$10.24B
2010-03-3140.75%$4.26B$1.25B$10.46B
2009-12-3145.45%$4.33B$915.40M$9.53B
2009-09-30-2.18%-$216M$941.80M$9.91B
2009-06-30-18.96%-$1.62B$1.16B$8.56B

Annual ROE

DateROENet income 12 monthShareholder equity
2024-12-3174.20%$10.59B$14.27B
2023-12-3148.23%$5.24B$10.86B
2022-12-3157.95%$6.24B$10.78B
2021-12-3160.97%$5.58B$9.15B
2020-12-31106.33%$6.19B$5.83B
2019-12-31308.19%$8.32B$2.7B
2018-12-3129.63%$3.23B$10.91B
2017-12-31-1.75%-$204.1M$11.67B
2016-12-3119.44%$2.74B$14.08B
2015-12-3116.51%$2.41B$14.59B
2014-12-3115.53%$2.39B$15.39B
2013-12-3126.56%$4.68B$17.64B
2012-12-3127.67%$4.09B$14.77B
2011-12-3132.12%$4.35B$13.54B
2010-12-3140.84%$5.07B$12.41B
2009-12-3145.45%$4.33B$9.53B
2008-12-31-30.75%-$2.07B$6.74B

Similar stocks

Stock NameCountryMarket CapPE Ratio
Akari Therapeutics Plc (AKTX)$1,527.991B-47,921.42
JOHNSON & JOHNSON (JNJ)United States$652.528B29.10
AbbVie Inc. (ABBV)United States$468.180B70.37
Merck & Co., Inc. (MRK)United States$365.215B99.96
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
PFIZER INC (PFE)United States$162.042B31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94